Redeye provides an update on Xbrane following the Q3 report, which beat our estimates on shipments to STADA, and the FDA approval of Lucamzi. With the regulatory risk removed, the refinancing of the Fenja loan and the Valorum renegotiation are now key, and we raise our fair value to SEK17.
LÄS MER
